NEW YORK, Aug. 2 – Compugen has licensed its LEADS computational biology platform to Novartis, the company announced on Thursday.
The deal, which will run for one year with the option for Novartis to extend two additional years, also includes a proprietary DNA chip design to represent Novartis’ transcriptome database. The deal is worth a "few million dollars" Compugen CEO Mor Amitai told GenomeWeb.
"For us this is a big deal," said Amitai. "Financially, it is substantial, and it [also] means working with one of the best functional genomics groups in the world. It is an imporant validation for us and our technologies." Amitai added that the agreement would allow Compugen to improve its tools based on Novartis' feedback.
The LEADS bioinformatics platform incorporates genomics and proteomics tools and public and proprietary databases. Other licensees include Human Genome Sciences and Pfizer.